Table 2.
Health indicators in the study participants receiving trimethoprim-sulfamethoxazole (TS) prophylaxis or no prophylaxis (the control group).
| Indicator | TS group (n = 157) |
Control group (n = 77) |
RR (95% CI) | P |
|---|---|---|---|---|
| Episodes of clinical malaria | 1/1890 (0.1) | 72/681 (10.6) | 0.005 (0.00–0.04) | <.001 |
| Asymptomatic parasitemia during monthly surveysa | 3/466 (0.6) | 43/231 (18.6) | 0.03 (0.01–0.11) | <.001 |
| Gastrointestinal illness | 68/1894 (3.6) | 49/933 (5.3) | 0.68 (0.47–0.99) | .04 |
| Respiratory illness | 78/1894 (4.1) | 37/933 (4.0) | 1.04 (0.70–1.54) | .77 |
| Use of all prescription medicines | 125/1894 (6.6) | 88/933 (9.4) | 0.70 (0.53–0.92) | .01 |
| Use of antibiotics | 11/1894 (0.6) | 8/933 (0.9) | 0.68 (0.27–1.69) | .41 |
| Increase in hemoglobin level, g/dL | 0.97 | 0.42 | … | .004 |
| Anemia during monthly surveysa | 20/471 (4.2) | 18/224 (8.0) | 0.53 (0.29–0.98) | .04 |
NOTE. Data are no. (%) of events/person-weeks of follow-up, unless otherwise noted. CI, confidence interval; RR, rate ratio.
a
Defined as a hemoglobin level <10 g/dL; includes results from surveys conducted 1, 2, and 3 months after the start of TS prophylaxis.